{"id":"NCT01074944","sponsor":"Genzyme, a Sanofi Company","briefTitle":"A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)","officialTitle":"A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2010-02-24","resultsPosted":"2016-12-02","lastUpdate":"2017-02-06"},"enrollment":170,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Gaucher Disease"],"interventions":[{"type":"DRUG","name":"Eliglustat tartrate","otherNames":["Genz-112638"]}],"arms":[{"label":"Twice Daily (BID) Dose Regimen","type":"EXPERIMENTAL"},{"label":"Once Daily (QD) Dose Regimen","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to evaluate the efficacy and safety of once daily (QD) versus twice daily (BID) dosing of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638). The secondary objective was to evaluate the pharmacokinetics (PK) of Genz-99067 when eliglustat tartrate (Genz-112638) was administered QD and BID in participants with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638).","primaryOutcome":{"measure":"PAP: Percentage of Participants Who Remained Stable for 52 Weeks During the PAP","timeFrame":"PAP Baseline up to the end of PAP (Week 52)","effectByArm":[{"arm":"PAP, Eliglustat: Once Daily","deltaMin":80.4,"sd":null},{"arm":"PAP, Eliglustat: Twice Daily","deltaMin":83.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":19},"locations":{"siteCount":46,"countries":["United States","Australia","Austria","Brazil","Canada","China","Croatia","France","Greece","India","Japan","Netherlands","Portugal","Romania","Russia","Serbia","Sweden"]},"refs":{"pmids":["17509920","20439622","20713962","29358012"],"seeAlso":["http://clinicaltrials.gov/ct2/show/NCT00891202?term=genz+ENGAGE&rank=1","http://clinicaltrials.gov/ct2/show/NCT00943111?term=genz+encore&rank=1"]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":170},"commonTop":["Nasopharyngitis","Headache","Arthralgia","Back pain","Dizziness"]}}